Skip to main content
    Back to Topics

    Mefloquine (Lariam) Exposure

    Last updated: May 2026
    White anti-malarial tablets spilled from an amber prescription bottle resting on a military desert camouflage uniform.
    General education only. This page describes how VA generally evaluates these claims under federal regulations. It is not legal advice and is not a recommendation about any individual claim. Every veteran's facts and evidence are different — for guidance on a specific situation, speak with a VA-accredited representative.

    What Mefloquine / Lariam is

    • Mefloquine is a quinoline anti-malarial that crosses the blood-brain barrier.
    • Side effects can include vivid dreams, anxiety, depression, psychosis, vertigo, balance disturbance, tinnitus, and confusion.
    • FDA 2013 black-box: 'serious or permanent' neurologic and psychiatric effects.
    • DoD restricted use in 2009 and again in 2013, making mefloquine a drug of last resort.

    Who was exposed

    • Service members deployed to malaria-endemic regions who were issued mefloquine prophylaxis.
    • Most commonly Somalia (1992 – 1993), Haiti (1994 – 1995), and post-9/11 deployments where doxycycline was contraindicated.
    • Service in Africa Command areas and certain Southeast Asia rotations.

    Recognized conditions & VA framework

    • Mefloquine Toxicity Syndrome (clinical syndrome — not a formal DSM diagnosis).
    • Vestibular dysfunction (chronic dizziness, vertigo, balance problems).
    • Anxiety and depressive disorders.
    • Psychotic disorders in severe cases.
    • Cognitive dysfunction and memory complaints.
    • Tinnitus (often filed alongside hearing loss claims).

    Evidence to gather

    • Pharmacy records or unit prescribing records showing mefloquine issued.
    • Pre- and post-deployment health assessment forms noting symptom onset.
    • Treating-provider notes documenting persistent neuropsychiatric symptoms.
    • Vestibular function testing if vertigo or balance is the primary complaint.
    • Buddy statements describing acute neuropsychiatric reactions during the deployment.
    • linking current symptoms to mefloquine exposure.

    Claim path

    1. File as — there is no mefloquine presumption.
    2. Cite the FDA black-box warning and DoD's own 2013 restrictions as evidence of recognized risk.
    3. Mental-health claims (PTSD, depression, anxiety) may stack — mefloquine exposure can be claimed as a separate or contributing cause.
    4. If a separate PTSD or depression is also viable, consider filing both etiologies in the alternative.

    Authoritative reference

    VA Public Health publishes its own overview of this exposure. Use it as a citation in your narrative: https://www.publichealth./exposures/mefloquine-lariam.asp

    Where these claims break down

    • ×Filing only for PTSD when mefloquine-attributed symptoms (vestibular, neurological) belong on the claim too.
    • ×Not requesting pharmacy or treatment records that document the prescription.
    • ×Skipping vestibular function testing for chronic dizziness claims.

    Frequently Asked Questions

    Useful Tools & Topics

    Have questions about your specific case?

    Every veteran's facts are different. A free initial consultation with a VA-Accredited Claims Agent can tell you whether your matter is a fit for representation — and what the right next step looks like either way.

    Disclaimer: This page is for educational purposes only and does not constitute legal advice. Oakridge Claims is a private business and is not affiliated with, endorsed by, or operated by the U.S. Department of Veterans Affairs. No guarantees of outcomes are made. Each claim is decided on its individual facts.

    Ready to Discuss Your Case?

    Reach out for a free consultation. We'll review your situation and discuss how Oakridge Claims can help.